Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.
Healio19h
Setmelanotide leads to significant decrease in BMI for patients with hypothalamic obesity
A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI ...